Lacosamide for the treatment of epilepsy

G. L. Krauss, H. B. Edwards, B. Lin

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Lacosamide is a third-generation antiepilepsy drug approved for adjunctive treatment of partial-onset seizures in adults. The pharmacology of lacosamide includes linear kinetics, complete bioavailability, and no major drug interactions. Lacosamide produces slow inactivation of neuronal sodium channels, which differentiates it from other sodium channel modulators, such as carbamazepine and phenytoin. The drug was effective with no major safety problems detected in three large placebo-controlled pivotal trials and has been released in Europe and the US at 200400 mg/day, divided b.i.d.; an intravenous formulation is approved for temporary conversion from oral therapy. This article reviews the clinical development, pharmacology, and uses of lacosamide for treating partial-onset seizures in adults.

Original languageEnglish (US)
Pages (from-to)674-679
Number of pages6
JournalAnnals of Medicine
Issue number7
StatePublished - Nov 2012


  • Antiepilepsy drugs
  • Epilepsy
  • Lacosamide

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Lacosamide for the treatment of epilepsy'. Together they form a unique fingerprint.

Cite this